Drug Repurposing Predictions — New Zealand

This project uses the TxGNN knowledge graph to predict potential new therapeutic uses for medicines approved in New Zealand.

Disclaimer: This content is for research purposes only and does not constitute medical advice. All drug repurposing predictions require clinical validation before application.

---

About the Developer

This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).

NZTxGNN is the New Zealand site of the company's "TxGNN Drug Repurposing" product line. The same system is deployed across 30 countries and regions, each named {CC}TxGNN (JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care. Product overview: https://www.yao.care/medical/txgnn/.

The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.